O Shaughnessy Asset Management LLC trimmed its holdings in DaVita Inc. (NYSE:DVA – Get Rating) by 61.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,636 shares of the company’s stock after selling 12,191 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in DaVita were worth $570,000 as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. Commerce Bank acquired a new stake in DaVita in the third quarter valued at approximately $323,000. Toronto Dominion Bank boosted its holdings in shares of DaVita by 3.4% in the 4th quarter. Toronto Dominion Bank now owns 24,161 shares of the company’s stock valued at $1,803,000 after buying an additional 792 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in DaVita by 39.4% during the 4th quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 142,991 shares of the company’s stock worth $10,677,000 after acquiring an additional 40,421 shares in the last quarter. Citigroup Inc. lifted its position in DaVita by 32.4% in the fourth quarter. Citigroup Inc. now owns 88,874 shares of the company’s stock valued at $6,636,000 after acquiring an additional 21,750 shares during the last quarter. Finally, Koss Olinger Consulting LLC grew its holdings in shares of DaVita by 96.9% during the third quarter. Koss Olinger Consulting LLC now owns 7,650 shares of the company’s stock worth $633,000 after purchasing an additional 3,764 shares during the last quarter. 86.52% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity at DaVita
In other DaVita news, Director Charles Berg sold 735 shares of the company’s stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $81.78, for a total transaction of $60,108.30. Following the transaction, the director now directly owns 17,164 shares in the company, valued at $1,403,671.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other DaVita news, Director Charles Berg sold 735 shares of the business’s stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $81.78, for a total transaction of $60,108.30. Following the sale, the director now directly owns 17,164 shares in the company, valued at $1,403,671.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Phyllis R. Yale sold 2,196 shares of the firm’s stock in a transaction on Friday, May 12th. The shares were sold at an average price of $95.26, for a total value of $209,190.96. Following the completion of the transaction, the director now owns 13,110 shares of the company’s stock, valued at approximately $1,248,858.60. The disclosure for this sale can be found here. Insiders sold 39,668 shares of company stock worth $3,889,765 over the last 90 days. Company insiders own 1.40% of the company’s stock.
DaVita Stock Performance
DaVita (NYSE:DVA – Get Rating) last released its quarterly earnings data on Monday, May 8th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.50. The firm had revenue of $2.87 billion during the quarter, compared to analysts’ expectations of $2.84 billion. DaVita had a return on equity of 72.08% and a net margin of 4.40%. DaVita’s revenue was up 2.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.61 earnings per share. Research analysts expect that DaVita Inc. will post 6.66 EPS for the current year.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on DVA. Bank of America upped their target price on DaVita from $86.00 to $96.00 in a research report on Tuesday, May 9th. UBS Group lifted their target price on shares of DaVita from $91.00 to $100.00 in a report on Tuesday, May 9th. Deutsche Bank Aktiengesellschaft increased their price target on shares of DaVita from $85.00 to $113.00 in a research note on Tuesday, May 9th. Sanford C. Bernstein upped their target price on shares of DaVita from $88.00 to $100.00 in a report on Monday, May 15th. Finally, Truist Financial raised their price target on DaVita from $90.00 to $100.00 in a report on Tuesday, May 9th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, DaVita currently has a consensus rating of “Hold” and a consensus target price of $96.88.
DaVita Profile
DaVita, Inc engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure.
See Also
- Get a free copy of the StockNews.com research report on DaVita (DVA)
- MarketBeat Week in Review – 5/22 – 5/26
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Get Rating).
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.
